Who we are.
With life sciences and medical device lawyers and experts located in key life science hubs across Michigan, Chicago and Washington D.C., we deeply understand the business and regulatory landscapes in which life sciences companies operate. We offer our clients an efficient value structure while providing a high-touch, interdisciplinary client experience backed by over seven decades of expertise in life science matters.
What we do.
We provide comprehensive support to life sciences and medical device companies and their investors at every stage of their journey, assisting them in navigating the challenges of a complex and heavily regulated environment while optimizing the value of their enterprise, intellectual property and human capital.
Who we work with.
We represent emerging growth companies, mid-size businesses and mature, multinational corporations across the spectrum of life sciences and medical device products and services.
How we work.
We work side-by-side with our clients to find the strategic paths that foster growth and minimize risk throughout all phases of the company life cycle. Motivated by the knowledge that the work we do with our clients is improving people’s lives, we serve as an extension of our clients’ teams so they can focus on their core business.
What we believe in.
We have a strong commitment to diversity, equity and inclusion. It is a fundamental part of our culture and our continued success. We truly believe that diversity and inclusion brings a broader perspective to our thinking, our client relationships and our work product. More importantly, it fosters an atmosphere of collegiality and respect, which is at the core of our firm’s values.
Regularly ranked by Chambers USA and listed in PitchBook as one of the most active private equity, M&A and venture capital firms in the United States, we have handled more than $84 billion in corporate transactions over the past three years.
Lawyers in our life sciences and medical devices practice are deeply experienced in corporate governance, financing and M&A transactions, capital raising transactions, collaborations and licensing, regulatory matters and intellectual property law.
As one of the nation’s leading law firms representing venture-backed companies, we have counseled thousands of entrepreneurs starting new businesses, advising on the formation of companies, equity structures, negotiations with investors, intellectual property rights, and other issues vital to their success. Our attorneys regularly represent clients involved in all aspects of the financing, operation, and sale of technology-based life sciences and medical device companies both in the United States and abroad. Our investor clients include institutional venture capital funds, strategic investors, venture capital fund-of-funds, and angel investors.
We have a long history of helping companies manage and mitigate risk involved in growth, taking venture capital, borrowing venture debt, and protecting and licensing technology from commercial and academic licensors.
We have further represented a variety of clients in restructuring transactions, including conversions from and to limited liability companies, to take best advantage of tax and operational considerations. We represent both investors and their portfolio companies in matters ranging from seed capital to growth equity for later-stage enterprises.
As part of our interdisciplinary approach, we also collaborate with attorneys in our patent litigation, products liability, employment and tax practices to protect client interests and to advocate on their behalf.
With a formidable national presence and an impressive team of over 120 legal professionals, our intellectual property lawyers represent top-tier pharmaceutical and biotechnology companies, large digital and high-tech companies, Fortune 100 companies, and start-ups and early stage companies to strategically manage and protect their IP portfolios at home and abroad. We are ranked among the top providers of IP services in the nation by our clients and by leading business and legal publications, including Chambers USA, LMG Life Sciences and Managing Intellectual Property. More than a third of our IP team hold advanced degrees, including PhDs, in disciplines such as biology, chemistry, computer science, electrical engineering, immunology, mechanical engineering, physics and more.
We provide full-spectrum counsel on domestic and foreign patents, trademarks, copyrights, trade secrets and know-how for clients in over 150 countries and help clients to protect and monetize their creative assets. Among other services, we routinely handle patent prosecution and strategic portfolio management, IP litigation, including patent infringement and ANDA-related disputes, copyright and trademark protection and enforcement, freedom-to-operate opinions and anti-counterfeiting strategies.
To help clients maximize the return on their IP investments, we regularly negotiate, execute and enforce a broad range of contracts and agreements, including joint research, development and commercialization agreements, clinical trial agreements, strategic alliances, licensing agreements, technology transfers between universities, medical centers and private industry, distribution networks, outsourcing and cloud-services agreements and other arrangements.
In a highly complex industry where advanced innovation demands an equally skilled workforce, we offer our clients a deep understanding of local and national employment laws so they can recruit and retain top-performing scientific, technological and leadership talent worldwide. We also help companies effectively manage their workforce through situational counseling, executive transition assistance, and the creation of policies and protective agreements.
Our business immigration attorneys have extensive expertise in navigating the complexities of the ever-evolving US immigration system. We regularly guide clients through H-1B visa, PERM labor certification and other processes and have helped individuals obtain O-1 status, immigrant alien of extraordinary ability status, outstanding researcher status, and other temporary and permanent visas, along with full citizenship in the United States.
As competition for skilled employees continues to rise, our employee benefits and executive compensation lawyers offer strategic, fiduciary and day-to-day counsel that helps businesses become employers of choice. Among other services, we regularly:
- Design, draft and correct plan documents, amendments and communications for tax-qualified and non-qualified retirement plans, including 401(k), 403(b), 457, profit-sharing, pension, cash-balance and deferred-compensation plans;
- Design and draft equity and cash incentive plans and arrangements, including bonus, retention, change-in-control, stock-option, restricted stock, along with other equity and compensation programs;
- Review third-party administrator and other service-provider agreements;
- Navigate benefits and compensation issues that arise in the context of corporate transactions; and
- Advise on compliance with IRS, ERISA, Patient Protection and Affordable Care Act (ACA), HIPAA and other laws and regulations.
Connect with a Professional
- Dennis J. Abdelnour
- Thomas J. Appledorn
- Denise M. Barnes
- Scott D. Barnett
- Jennifer L. Benedict
- John (Jack) J. Carver
- James H. Combs
- Justin M. Crawford
- Sean F. Crotty
- Kathryn D. Doyle
- David A. Ettinger
- Harold Fox, Ph.D.
- Carol A. Friend
- John Hertel
- Karl A. Hochkammer, CIPP/US
- Rachel M. Hofstatter
- J. Michael Huget
- John P. Kanan
- Barbara A. Kaye
- Matthew Keuten
- Anessa Owen Kramer
- Tracy T. Larsen
- Vikram A. Mathrani
- Kelly T. Murphy
- Ilan Napchan
- Jonathan P. O'Brien, Ph.D.
- David N. Parsigian
- Mark S. Pendery
- Phillip D. Torrence
- Matthew R. VanWasshnova
- Andrew N. Weber
- Steven M. Wernikoff
News & Insights
Represented Elucid Bioimaging, Inc. in its $80 million Series C Funding Round
We have handled more than $84 billion in corporate transactions over the past three years
We have worked on 20+ FDA-approved drugs
We have led over a dozen investor-side and company-side patent due diligence investigations
We are actively assisting clients with over two dozen drugs that are currently in Phase 2 or Phase 3 clinical development